PharmaNutrients Gains Patent for CLA One
The company reports that by modulating specific hormones and inflammatory molecules such as cytokines and eicosanoids before or at time of stress, CLA One can influence those physiological processes associated with catabolic stress response.
“During the course of our research at Penn State, we discovered CLA One could reduce pro-inflammatory cytokines,” stated Dr. Susie Rockway, Director of Research and Development at PharmaNutrients and one of the lead inventors of the patent. “By modulating specific hormones and inflammatory molecules such as cytokines and eicosanoids before or at time of stress, CLA One can influence those physiological processes associated with catabolic stress response.”
Recently, the FDA has withdrawn several pharmaceutical products due to dangerous side-effects; in fact, some cases have resulted in death. This has fueled a growing need for a safer, natural, scientifically validated alternative like CLA One. Working by effectively reducing the expression of IL-1, IL-6, , CLA One thereby minimizes the stimulation or propagation of thePGE2 and TNF stress response.
“Many acute and chronic illnesses are associated with a metabolic stress condition,” said Dr. Rockway. “I’m pleased that our patent will benefit in the treatment of these chronic conditions and that PharmaNutrients can play a positive role in promoting wellness.”
Mark Nottoli, President and founder of PharmaNutrients explained, “It has been PharmaNutrients’ strategy to create new technologies and applications for CLA beyond the initial role we identified in body composition. The new patent serves to strengthen and reinforce our patent portfolio supporting applications for cardiovascular health. This patent allows us to provide our customers with exclusive and unique, patent-protected products.”
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
